PL438134A1 - Glikokoniugatowa pochodna metotreksatu i glukozy oraz sposób jej otrzymywania i jej zastosowanie w leczeniu i zapobieganiu nowotworom - Google Patents
Glikokoniugatowa pochodna metotreksatu i glukozy oraz sposób jej otrzymywania i jej zastosowanie w leczeniu i zapobieganiu nowotworomInfo
- Publication number
- PL438134A1 PL438134A1 PL438134A PL43813421A PL438134A1 PL 438134 A1 PL438134 A1 PL 438134A1 PL 438134 A PL438134 A PL 438134A PL 43813421 A PL43813421 A PL 43813421A PL 438134 A1 PL438134 A1 PL 438134A1
- Authority
- PL
- Poland
- Prior art keywords
- cancer
- prevention
- treatment
- methotrexate
- glucose
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical class C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 title abstract 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 title abstract 2
- 239000008103 glucose Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010055008 Gastric sarcoma Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Przedmiotem wynalazku jest nowa glikokoniugatowa pochodna metotreksatu i glukozy oraz sposób jej otrzymywania oraz jej zastosowanie w leczeniu i zapobieganiu nowotworom, korzystnie w leczeniu i zapobieganiu nowotworom wybranym spośród: raka skóry, raka jelita grubego, raka piersi, raka żołądka, mięsaka i raka płuc.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL438134A PL243572B1 (pl) | 2021-06-11 | 2021-06-11 | Glikokoniugatowa pochodna metotreksatu i glukozy oraz sposób jej otrzymywania i jej zastosowanie w leczeniu i zapobieganiu nowotworom |
| PCT/PL2022/050036 WO2022260545A1 (en) | 2021-06-11 | 2022-06-13 | Synthesis of a novel glucose-conjugated methotrexate and its application for the treatment and prevention of neoplasms |
| EP22820643.9A EP4352072B1 (en) | 2021-06-11 | 2022-06-13 | Synthesis of a novel glucose-conjugated methotrexate and its application for the treatment and prevention of neoplasms |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL438134A PL243572B1 (pl) | 2021-06-11 | 2021-06-11 | Glikokoniugatowa pochodna metotreksatu i glukozy oraz sposób jej otrzymywania i jej zastosowanie w leczeniu i zapobieganiu nowotworom |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL438134A1 true PL438134A1 (pl) | 2022-12-12 |
| PL243572B1 PL243572B1 (pl) | 2023-09-11 |
Family
ID=84426204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL438134A PL243572B1 (pl) | 2021-06-11 | 2021-06-11 | Glikokoniugatowa pochodna metotreksatu i glukozy oraz sposób jej otrzymywania i jej zastosowanie w leczeniu i zapobieganiu nowotworom |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4352072B1 (pl) |
| PL (1) | PL243572B1 (pl) |
| WO (1) | WO2022260545A1 (pl) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL228735B1 (pl) * | 2012-02-27 | 2018-04-30 | Inst Immunologii I Terapii Doswiadczalnej Pan | Zastosowanie koniugatu składającego się z nośnika i zawiązanego z nim kowalencyjnie leku |
| PL242529B1 (pl) * | 2018-08-20 | 2023-03-06 | Univ Medyczny Im Piastow Slaskich We Wroclawiu | Glikokoniugatowa pochodna metotreksatu i glukozy, jej zastosowanie oraz sposób otrzymywania |
| PL243573B1 (pl) * | 2021-06-11 | 2023-09-11 | Univ Medyczny Im Piastow Slaskich We Wroclawiu | Koniugat metotreksatu i glukozy do zastosowania w zapobieganiu lub leczeniu chorób autoimmunologicznych |
-
2021
- 2021-06-11 PL PL438134A patent/PL243572B1/pl unknown
-
2022
- 2022-06-13 WO PCT/PL2022/050036 patent/WO2022260545A1/en not_active Ceased
- 2022-06-13 EP EP22820643.9A patent/EP4352072B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4352072B1 (en) | 2026-02-04 |
| WO2022260545A1 (en) | 2022-12-15 |
| EP4352072A1 (en) | 2024-04-17 |
| PL243572B1 (pl) | 2023-09-11 |
| EP4352072C0 (en) | 2026-02-04 |
| EP4352072A4 (en) | 2025-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
| EP4684786A3 (en) | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer | |
| MX2022010224A (es) | Compuestos que interactuan con la superfamilia ras para el tratamiento de canceres, enfermedades inflamatorias, rasopatias y enfermedad fibrotica. | |
| MX2025011947A (es) | Inhibidores macrociclicos de ras | |
| MX2023013912A (es) | Metodos para inhibir ras. | |
| MX2021014137A (es) | Pertuzumab para usarse en el tratamiento de cancer de mama her2 positivo. | |
| EP4233909A3 (en) | Anti-cmet antibody drug conjugates and methods for their use | |
| CA3055791A1 (en) | Treatment methods | |
| ZA201907225B (en) | Treatment of her2 positive cancers | |
| WO2019197605A3 (en) | Drug combinations for use in the treatment of ras-mutant cancer | |
| EA201792162A1 (ru) | Способы введения ингибиторов глутаминазы | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| MX2025012181A (es) | Formas cristalinas de inhibidores de ras, composiciones que las contienen y metodos para su uso | |
| EP3064509A3 (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer | |
| NO20085147L (no) | Sammensetning for behandling av motstandsdyktige kreftformer omfattende oridonin | |
| EA201792294A1 (ru) | Комбинированное лечение (варианты) с применением серибантумаба | |
| MX2026002367A (es) | Composiciones de copolimero de bloque sensibles al ph, micelas, y metodos de uso | |
| MX2025000673A (es) | Metodos de administracion de nalbufina | |
| IS8064A (is) | Notkun ísókínólínafleiða til að meðhöndla krabbamein og sjúkdóma sem tengjast MAP kínasa | |
| WO2022214869A3 (en) | 2,4-diaminopyrimidine derivatives as ulk1/2 inhibitors and their use thereof | |
| WO2009091230A3 (ko) | 유방암 모니터링,진단 및 스크리닝용 단백질 마커 및 이를 이용한 유방암 모니터링,진단 및 스크리닝 방법 | |
| WO2020102243A3 (en) | In-flow photooxygenation of aminothienopyridinones generates novel ptp4a3 phosphatase inhibitors | |
| BR112021016923A2 (pt) | Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits | |
| PL435353A1 (pl) | Preparat z liofilizowanych jaj ślimaków Helix aspersa maxima i wodny ekstrakt z tego preparatu oraz sposób ich otrzymywania i zastosowanie | |
| PL426731A1 (pl) |